What is Synbio Technologies?
Synbio Technologies is a prominent player in the synthetic biology arena, offering a comprehensive suite of services designed to accelerate scientific discovery and development. Their expertise spans gene synthesis, protein expression, and gene editing, providing researchers worldwide with high-precision, cost-effective custom synthetic biology products that adhere to stringent manufacturing standards. The company's innovative solutions extend to oligonucleotide diagnostics, recombinant collagen, and AI-driven protein production, positioning them as a vital partner for advancing biological research and enabling breakthroughs.
How much funding has Synbio Technologies raised?
Synbio Technologies has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Synbio Technologies
PPP
Public-Private Partnership
What's next for Synbio Technologies?
With substantial late-stage funding, Synbio Technologies is poised for significant expansion and further innovation. The recent strategic investment signals strong confidence from backers in the company's trajectory and its capacity to scale its operations and technological capabilities. This capital infusion will likely fuel advancements in their AI-enhanced protein production and recombinant collagen offerings, potentially leading to new market opportunities and solidifying their leadership in the synthetic biology industry. The company's focus on providing one-stop solutions suggests a strategy aimed at capturing a larger share of the global research and manufacturing market.
See full Synbio Technologies company page
